Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen Rollover Extension in Elevated Lp(a) and ASCVD
NCT06875973Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2025
- Primary completion
- Dec 2030
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 3 trial of pelacarsen in atherosclerotic cardiovascular disease (ASCVD), sponsored by Novartis. Started May 2025; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06875973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875973.